MedTrace Logo

Effect of Ketoconazole on Biliary Excretion of AZD0837

NCT00812344 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-12-03

No results posted yet for this study

Summary

This is an explorative study and the scientific question to be investigated is if the biliary excretion of AZD0837 and its metabolites AR-H069927XX and AR-H067637XX are affected by co-administration with ketoconazole

Conditions

  • Healthy

Interventions

DRUG

AZD0837

Oral solution, dosing through the Loc-I-Gut catheter, single dose

DRUG

Ketoconazole

tablets, orally, once daily for 3 days

DRUG

ketoconazole

dissolved tablets, dosing through the Loc-I-Gut catheter, single dose

Sponsors & Collaborators

Principal Investigators

  • Lars Knutson, MD, PhD · Inst för Kirurgiska VetenskaperUppsala Universitet

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812344 on ClinicalTrials.gov